Overview Safety and Tolerability of LIM-0705 in Healthy Male Subjects Status: Completed Trial end date: 2010-06-01 Target enrollment: Participant gender: Summary LIM-0705 dosed separately and in combination with tacrolimus will be safe and well tolerated. Phase: Phase 1 Details Lead Sponsor: Limerick BioPharmaTreatments: Tacrolimus